Cargando…

Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model

Hepatic fibrosis is the wound-healing process of chronic hepatic disease that leads to the end-stage of hepatocellular carcinoma and demolition of hepatic structures. Epithelial–mesenchymal transition (EMT) has been identified to phenotypic conversion of the epithelium to mesenchymal phenotype that...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwon, Mi-Gyeong, Kim, Jung-Yeon, An, Hyun-Jin, Kim, Woon-Hae, Gu, Hyemin, Kim, Min-Kyung, Pak, Sok Cheon, Park, Kwan-Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222866/
https://www.ncbi.nlm.nih.gov/pubmed/30103395
http://dx.doi.org/10.3390/molecules23081991
_version_ 1783369307130953728
author Gwon, Mi-Gyeong
Kim, Jung-Yeon
An, Hyun-Jin
Kim, Woon-Hae
Gu, Hyemin
Kim, Min-Kyung
Pak, Sok Cheon
Park, Kwan-Kyu
author_facet Gwon, Mi-Gyeong
Kim, Jung-Yeon
An, Hyun-Jin
Kim, Woon-Hae
Gu, Hyemin
Kim, Min-Kyung
Pak, Sok Cheon
Park, Kwan-Kyu
author_sort Gwon, Mi-Gyeong
collection PubMed
description Hepatic fibrosis is the wound-healing process of chronic hepatic disease that leads to the end-stage of hepatocellular carcinoma and demolition of hepatic structures. Epithelial–mesenchymal transition (EMT) has been identified to phenotypic conversion of the epithelium to mesenchymal phenotype that occurred during fibrosis. Smad decoy oligodeoxynucleotide (ODN) is a synthetic DNA fragment containing a complementary sequence of Smad transcription factor. Thus, this study evaluated the antifibrotic effects of Smad decoy ODN on carbon tetrachloride (CCl(4))-induced hepatic fibrosis in mice. As shown in histological results, CCl(4) treatment triggered hepatic fibrosis and increased Smad expression. On the contrary, Smad decoy ODN administration suppressed fibrogenesis and EMT process. The expression of Smad signaling and EMT-associated protein was markedly decreased in Smad decoy ODN-treated mice compared with CCl(4)-injured mice. In conclusion, these data indicate the practicability of Smad decoy ODN administration for preventing hepatic fibrosis and EMT processes.
format Online
Article
Text
id pubmed-6222866
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62228662018-11-13 Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model Gwon, Mi-Gyeong Kim, Jung-Yeon An, Hyun-Jin Kim, Woon-Hae Gu, Hyemin Kim, Min-Kyung Pak, Sok Cheon Park, Kwan-Kyu Molecules Article Hepatic fibrosis is the wound-healing process of chronic hepatic disease that leads to the end-stage of hepatocellular carcinoma and demolition of hepatic structures. Epithelial–mesenchymal transition (EMT) has been identified to phenotypic conversion of the epithelium to mesenchymal phenotype that occurred during fibrosis. Smad decoy oligodeoxynucleotide (ODN) is a synthetic DNA fragment containing a complementary sequence of Smad transcription factor. Thus, this study evaluated the antifibrotic effects of Smad decoy ODN on carbon tetrachloride (CCl(4))-induced hepatic fibrosis in mice. As shown in histological results, CCl(4) treatment triggered hepatic fibrosis and increased Smad expression. On the contrary, Smad decoy ODN administration suppressed fibrogenesis and EMT process. The expression of Smad signaling and EMT-associated protein was markedly decreased in Smad decoy ODN-treated mice compared with CCl(4)-injured mice. In conclusion, these data indicate the practicability of Smad decoy ODN administration for preventing hepatic fibrosis and EMT processes. MDPI 2018-08-10 /pmc/articles/PMC6222866/ /pubmed/30103395 http://dx.doi.org/10.3390/molecules23081991 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gwon, Mi-Gyeong
Kim, Jung-Yeon
An, Hyun-Jin
Kim, Woon-Hae
Gu, Hyemin
Kim, Min-Kyung
Pak, Sok Cheon
Park, Kwan-Kyu
Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model
title Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model
title_full Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model
title_fullStr Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model
title_full_unstemmed Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model
title_short Antifibrotic Effect of Smad Decoy Oligodeoxynucleotide in a CCl(4)-Induced Hepatic Fibrosis Animal Model
title_sort antifibrotic effect of smad decoy oligodeoxynucleotide in a ccl(4)-induced hepatic fibrosis animal model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222866/
https://www.ncbi.nlm.nih.gov/pubmed/30103395
http://dx.doi.org/10.3390/molecules23081991
work_keys_str_mv AT gwonmigyeong antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel
AT kimjungyeon antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel
AT anhyunjin antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel
AT kimwoonhae antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel
AT guhyemin antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel
AT kimminkyung antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel
AT paksokcheon antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel
AT parkkwankyu antifibroticeffectofsmaddecoyoligodeoxynucleotideinaccl4inducedhepaticfibrosisanimalmodel